L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 8.6 NOK -0.92% Market Closed
Market Cap: 587m NOK

Operating Margin
Lytix Biopharma AS

-14 909.5%
Current
-3 040%
Average
-5%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-14 909.5%
=
Operating Profit
-90.7m
/
Revenue
608k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
NO
Lytix Biopharma AS
OSE:LYTIX
587.1m NOK
-14 910%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
335.3B USD
30%
US
Amgen Inc
NASDAQ:AMGN
156.1B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
140B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
117.1B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
53.4B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.2B USD
-5%

Lytix Biopharma AS
Glance View

Market Cap
587.1m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.14 NOK
Overvaluation 98%
Intrinsic Value
Price
L
What is Intrinsic Value?

See Also

Summary
LYTIX intrinsic value, competitors valuation, and company profile.
DCF Valuation
LYTIX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LYTIX stock valuation using valuation multiples.
Wall Street Estimates
LYTIX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LYTIX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-14 909.5%
=
Operating Profit
-90.7m
/
Revenue
608k
What is the Operating Margin of Lytix Biopharma AS?

Based on Lytix Biopharma AS's most recent financial statements, the company has Operating Margin of -14 909.5%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 260,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.